Drug intelligence / Profile preview

reidispongiolide c

Development stage: Preclinical
Modality: Small Molecules

Overview

Reidispongiolide C is a bioactive polyketide macrolide compound isolated from marine sponges, specifically as a minor metabolite in the reidispongiolide/sphinxolide family. It features a complex macrocyclic structure and is classified as a diterpene lactone. Reidispongiolides, including C, are known for their potent cytotoxic properties and ability to destabilize microfilaments by targeting actin filaments within cells. The mechanism involves binding to the barbed end of actin, leading to inhibition of actin filament assembly and disruption of cytoskeletal dynamics, which can result in cell death. This makes them promising leads for anticancer drug development due to their unique mode of action and ability to circumvent multidrug resistance[1][7][8].

Other names: reidispongiolide c

Targets

Actin filament proteins

Beyond the preview

Go deeper on reidispongiolide c.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on reidispongiolide c.

Explore the full profile